ProCE Banner Activity

Long-term Survival With Blinatumomab and Allogeneic HSCT in B-Cell Precursor Acute Lymphoblastic Leukemia

Slideset Download
Conference Coverage
Retrospective analysis suggests that sequential use of blinatumomab and HSCT may benefit patients with BCP-ALL, particularly in younger patients.

Released: June 08, 2018

Expiration: June 07, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen